Institute for Cancer Research

Kjetil Taskén
Instiute head

Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded. Read more

See introductory video with welcome to the ICR 

See full video covering all of ICR and its Departments 

Publication overview

Annual reports

 

Current news and events

New vaccine therapy against multi-resistant tuberculosis bacteria is under development

From left: Synne Jenum, Kristian Tonby (shared first authors) and Anne Ma Dyrhol Riise (senior author)
From left: Synne Jenum, Kristian Tonby (shared first authors) and Anne Ma Dyrhol Riise (senior author)
In response to the serious tuberculosis situation in the world, researchers at Oslo University Hospital have for the first time tested a vaccine developed by Danish researchers at the Center for Vaccine Research at the Statens Serum Institut in patients with tuberculosis. 
"Tuberculosis disease occurs when the immune system is no longer able to control the bacteria in people that may have been infected a long time ago. The idea of therapeutic vaccination is to help the immune system to be able to better fight the infection while receiving antibiotic treatment. " says Anne Ma Dyrhol-Riise, chief physician at the Department of Infectious Diseases, Oslo University Hospital and project manager for the clinical study.

Dec 7 12-13 Aud FOBY:Horisont Europa: Cancer Mission Q&A

OUS-CCC is hosting a seminar on Horisont Europa and EUs Cancer Mission.
Time:  Tuesday Dec 7 12-13
Place: Auditorium FOBY, K01-Radiumhospitalet.

This is a great opportunity to ask questions about participation in European research networks and how research funding will be organized, so please send your questions to anders.overbye@medisin.uio.no by Fri 3/12.

New ICT platform:Forskningsportalen survey - deadline extended to Dec 8

In 2022, a new ICT platform, Forskningsportalen, will be established and made available for researchers at OUS and HSØ. The new portal will offer access to a flexible and sharable workspace, some computing capacity and data storage. The migration will start slowly with some pilot projects and will then be extended over time. When all data has been securely migrated, the plan is to terminate Forskernett.

All users on Forskernett are asked to complete a survey with deadline on Dec 8 (extended) to prepare for the migration process. 

 

Dutch-Nordic Alliance for Precision Cancer Medicine launched

The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.

‘This is "a triple win” - for cancer patients, investigators and industry partners’, says Kjetil Tasken from IMPRESS-Norway, ‘as we will generate and gather evidence more rapidly on very rare combinations of diagnosis, mutation and treatment to allow for early implementation of new cancer medicines.’

Kay Oliver Schink identifies a new regulator of macropinocytosis, an important mechanism for nutrient acquisition by cancer cells

First author Kay Oliver Schink (left) and last author Harald Stenmark
First author Kay Oliver Schink (left) and last author Harald Stenmark

In a recent article in Nature Communications, published online on the 12 of November, 2021, project group leader Kay Oliver Schink and his coworkers in Harald Stenmark’s group at the Institute for Cancer Research and the Centre for Cancer Cell Reprogramming (CanCell) identify a new mechanism how the protein Phafin2 can regulate a process called “macropinocytosis”.

Units and subpages

View all subunitsHide all subunits